NRX Pharmaceuticals (NRXP) Research & Development (2020 - 2026)

NRX Pharmaceuticals (NRXP) has 7 years of Research & Development data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Research & Development rose 62.81% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $4.3 million, a 18.5% decrease from a year earlier, with the FY2025 full-year figure at $3.8 million, down 39.07% from the prior year.
• Research & Development for Q1 2026 stood at $1.3 million, up from $558000.0 in the prior quarter.
• Over the last five years, Research & Development for NRXP reached as high as $5.5 million in Q1 2022 and fell as low as $558000.0 in Q4 2025.
• Historically, Research & Development has averaged $2.3 million across 5 years, with a median of $1.7 million in 2024.
• Across the five-year window, Research & Development sank 85.34% in 2023 and soared 133.88% in 2025, its largest moves.
• Year by year, Research & Development stood at $4.5 million in 2022, then sank by 43.13% to $2.5 million in 2023, then sank by 59.12% to $1.0 million in 2024, then slumped by 46.14% to $558000.0 in 2025, then jumped by 134.59% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $1.3 million in Q1 2026, $558000.0 in Q4 2025, and $1.4 million in Q3 2025.